Xi-Chun Hu (Xichun Hu)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 22

Top Topics

Tyrosine Kinase

Dna Damage Response

Metastatic Breast Cancer

Top Venues

Cancer medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Jianing Cao, Mengdi Yang, Duancheng Guo, Zhonghua Tao, Xi-Chun Hu
Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer. Cancer medicine 13 (14) (2024)
Jianing Cao, Mengdi Yang, Duancheng Guo, Zhonghua Tao, Xi-Chun Hu
Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer. Cancer medicine 13 (14) (2024)
Jianing Cao, Mengdi Yang, Duancheng Guo, Zhonghua Tao, Xi-Chun Hu
Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer. Cancer medicine 13 (14) (2024)
Juan Jin, Bin Li, Jianing Cao, Ting Li, Jian Zhang, Jun Cao, Mingchuan Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. Journal of translational medicine 21 (1) (2023)
Juan Jin, Jianing Cao, Bin Li, Ting Li, Jian Zhang, Jun Cao, Mingchun Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer (2023)
Bin Li, Juan Jin, Duancheng Guo, Zhonghua Tao, Xi-Chun Hu
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers 15 (10) (2023)
Juan Jin, Jianing Cao, Bin Li, Ting Li, Jian Zhang, Jun Cao, Mingchun Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer 129 (6) (2023)
Xin-Yu Chen, Bin Li, Ye Wang, Juan Jin, Yu Yang, Lei-Huan Huang, Meng-Di Yang, Jian Zhang, Bi-Yun Wang, Zhi-Ming Shao, Ting Ni, Sheng-Lin Huang, Xi-Chun Hu, Zhong-Hua Tao
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Cancer communications (London, England) (2023)
Juan Jin, Jianing Cao, Bin Li, Ting Li, Jian Zhang, Jun Cao, Mingchun Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer 129 (6) (2023)
Bin Li, Weiqi Xu, Jianing Cao, Duancheng Guo, Zhonghua Tao, Juan Jin, Xi-Chun Hu
A study of clinical and molecular characteristics in bilateral primary breast cancer. Cancer medicine (2023)
Quchang Ouyang, Ying Wang, Jian Zhang, Qiong Wu, Hongying Wei, Chuan Li, Xiaoling Qian, Xi-Chun Hu
HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial. Cancer medicine (2023)
Juan Jin, Jianing Cao, Bin Li, Ting Li, Jian Zhang, Jun Cao, Mingchun Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer 129 (6) (2023)
Juan Jin, Jianing Cao, Bin Li, Ting Li, Jian Zhang, Jun Cao, Mingchun Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xi-Chun Hu
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation. Cancer 129 (6) (2023)
Yizhao Xie, Cheng Liu, Yannan Zhao, Chengcheng Gong, Yi Li, Shihui Hu, Shaoli Song, Xi-Chun Hu, Zhongyi Yang, Bi-Yun Wang
Heterogeneity derived from 18 F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients. Cancer medicine 11 (9) (2022)
Jian Zhang, Dongmei Ji, Weina Shen, Qin Xiao, Yajia Gu, Joyce O'Shaughnessy, Xi-Chun Hu
Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jian Zhang, Dongmei Ji, Weina Shen, Qin Xiao, Yajia Gu, Joyce O'Shaughnessy, Xi-Chun Hu
Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jia Jin, Yilin Shao, Jian Zhang, Junning Cao, Zhonghua Tao, Xi-Chun Hu
High-purity isolation platelets by gradient centrifugation plus filtration. International journal of laboratory hematology (2022)
Bi-Yun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nature communications 13 (1) (2022)
Yihui Zhu, Zhonghua Tao, Ying Chen, Shuchen Lin, Mingyu Zhu, Wei Ji, Xiaojia Liu, Ting Li, Xi-Chun Hu
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT. Breast cancer research and treatment 193 (1) (2022)
Leiping Wang, Jun Cao, Chunlei Li, Xiaodong Wang, Yannan Zhao, Ting Li, Yiqun Du, Zhonghua Tao, Wenxia Peng, Biyun Wang, Jian Zhang, Sheng Zhang, Zhonghua Wang, Xi-Chun Hu
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. Investigational new drugs (2021)
Ting Li, Zhonghua Tao, Yihui Zhu, Xiaojia Liu, Leiping Wang, Yiqun Du, Jun Cao, Biyun Wang, Jian Zhang, Xi-Chun Hu
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. Cell death & disease 12 (7) (2021)
Yilin Shao, Xin Liu, Silong Hu, Yingjian Zhang, Wentao Li, Xiaoyan Zhou, Qifeng Wang, Yifeng Hou, Yong Chen, Yanli Wang, Yaohui Wang, Zhiguo Luo, Xi-Chun Hu
Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. BMC cancer 20 (1) (2020)